| Autor: |
Hiroshi BANDO, Hisako YAMASHITA, Yoshinobu KATO, Katsunori OGURA, Yoshikane KATO |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Asploro Journal of Biomedical and Clinical Case Reports. 6:69-75 |
| ISSN: |
2582-0370 |
| DOI: |
10.36502/2023/asjbccr.6293 |
| Popis: |
Background: Vildagliptin/Metformin (EquMet) and imeglimin (Twymeeg) are effective oral hypoglycemic agents (OHAs) for patients with type 2 diabetes (T2D). Case Presentation: The patient was a 68-year-old male with T2D and fatty liver for several years. In November 2022, his HbA1c had increased to 8.2%, and he was started on Twymeeg, followed by EquMet. Results: Over the course of four months, the patient’s HbA1c value successfully decreased from 8.2% to 6.7%, and he did not experience any gastrointestinal adverse effects (GIAEs). Discussion and Conclusion: The combined treatment of EquMet and Twymeeg demonstrated clinical efficacy without any adverse effects. The Trials of IMeglimin for Efficacy and Safety (TIMES) provided various evidence of imeglimin’s effectiveness. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
